Search results
Results From The WOW.Com Content Network
CPA/EE-containing birth control pills were developed by 1975 [20] [21] and were first introduced for medical use in 1978. [22] They originally contained 50 μg EE (Diane); subsequently, the EE dosage was decreased to 35 μg in a new "low-dose" preparation in 1986 (Diane-35). [4] [23] [24]
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
All contain an estrogen, ethinylestradiol or mestranol, [1] [2] in varying amounts, and one of a number of different progestogens. (Regarding the estrogen, the inactive 3-methyl ether of ethinylestradiol, which must be metabolized by the liver into the active ethinylestradiol; 50 μg of mestranol is equivalent to only 35 μg of ethinylestradiol and should not be used when high-dose [50 μg ...
The progestogen-only pill, colloquially known as "minipill". For perfect use it is 99% effective and typical use is 91% effective. Side effects of the pill include headache, dizziness, nausea, sore breasts, spotting, mood changes, acne, bloating, etc. [clarification needed] One pill offers the benefit of only having to be taken once a week:
Different sources note different incidence of side effects. The most common side effect is breakthrough bleeding. Combined oral contraceptive pills can improve conditions such as dysmenorrhea, premenstrual syndrome, and acne, [105] reduce symptoms of endometriosis and polycystic ovary syndrome, and decrease the risk of anemia. [106]
Ethinylestradiol (EE) is an estrogen medication which is used widely in birth control pills in combination with progestins. [7] [8] In the past, EE was widely used for various indications such as the treatment of menopausal symptoms, gynecological disorders, and certain hormone-sensitive cancers.
Mestranol/norethynodrel was the first combined oral contraceptive pill (COCP) being mestranol and norethynodrel. It sold as Enovid in the United States and as Enavid in the United Kingdom . Developed by Gregory Pincus at G. D. Searle & Company , it was first approved on June 10, 1957, by the U.S. Food and Drug Administration for treatment of ...
Extended or continuous use of COCPs or other combined hormonal contraceptives carries the same risk of side effects and medical risks as traditional COCP use. [citation needed] Pill Failure can happen with contraceptive pills and inadvertent pregnancies happen. [20] Use of oral contraceptive can impair muscle gains in young women. [21]